HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inter Parfums

This article was originally published in The Rose Sheet

Executive Summary

Purchase of Tristar fragrances may provide opportunity to expand distribution of mass market brands into Wal-Mart, CEO Jean Madar says during Q1 sales and earnings release May 14. Firm's wholly-owned subsidiary recently received approval of purchase from San Antonio Bankruptcy Court and expects to close definitive agreement by end of the month (1"The Rose Sheet" May 6, 2002, In Brief). Inter Parfums mass market sales increased 9% on strong performances by Aziza and Intimate health and beauty aids, while prestige fragrances were down 10% in constant dollars, reflecting fewer launches compared with same period last year. Net sales declined 8.5% to $28.4 mil. and net income fell 1% to $2 mil...

You may also be interested in...



Inter Parfums buy

Sales from acquired Tristar mass market fragrance brands could reach $15 mil. within 12 months, fragrance marketer says. Inter Parfums' wholly-owned subsidiary, Jean Philippe Fragrances, received approval from San Antonio, Texas bankruptcy court to buy certain Tristar trademarks and intellectual property for $3.5 mil. and inventory for $4.7 mil., firm announces May 1. Tristar's fragrance portfolio includes Royal, Royal Crown II, Regal and Club Exclusive. Formal purchase agreement to be signed shortly; deal is expected to close by June 1. Fragrance Impressions, a newly formed company owned by Tristar management, will purchase remaining assets of Tristar. Jean Philippe announced its bid in March following Tristar's Chapter 11 filing (1"The Rose Sheet" March 18, 2002, p. 3)...

Impella Safety Update: Data Supports Pump For Qualified Patients

Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.

Quality, Safety, MDSAP A Focus For Medtech In New USMCA Trade Agreement

The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.

UsernamePublicRestriction

Register

RS010297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel